Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Monday 14 April, 2003

Xenova Group PLC

Research Update

Xenova Group PLC
14 April 2003

                                Xenova Group plc

      Patient Dosing Begins in Phase IIa Cocaine Administration Trial for
                      Anti-Cocaine Addiction Vaccine TA-CD

Slough, UK, 14th April 2003 - Xenova Group plc (Nasdaq NM: XNVA; London Stock
Exchange: XEN) today announced that patient dosing has begun in a Phase IIa
cocaine administration trial for Xenova's therapeutic vaccine TA-CD, which is
under development for the treatment of cocaine addiction. The ten-patient open
label trial is being conducted in the United States and is designed to evaluate
the effect of TA-CD on behavioural changes associated with cocaine

Cocaine-dependent volunteers, specifically selected from those not seeking to
quit, undergo psychological and physiological assessments whilst cocaine is
administered under laboratory conditions.  The effect of TA-CD will be
determined by comparing findings from before and after a four-dose immunisation
course. This study is being funded, in part, by the US National Institute on
Drug Abuse (NIDA). NIDA has also supported earlier clinical work on TA-CD. TA-CD
is the first vaccine to be developed with the goal of assisting cocaine abusers
in their attempt to quit cocaine.

Previous clinical studies have shown that administration of TA-CD leads to the
generation of antibodies that can bind free cocaine.  TA-CD is a cocaine
derivative conjugated to a carrier protein and formulated with an adjuvant.
Ultimately, it is intended for use alongside behavioural therapy programmes in
patients who are trying actively to overcome their cocaine addiction.

Cocaine abusers who make an attempt to quit are at risk of relapse if they '
slip' and use cocaine.  By vaccinating those who wish to quit, it is intended
that if the patient 'slips' the cocaine will bind to antibodies in the blood
stream and interfere with the ability of the cocaine to enter the brain and
stimulate the reward centres.  The objective of vaccination with TA-CD is to
reduce the euphoria obtained by the individual, thus diminishing the reinforcing
effects of cocaine and increasing the likelihood of a successful attempt to

Currently, there is no effective pharmacotherapy available for the approximately
900,000 individuals in the USA each year who seek medical help with respect to
their cocaine addiction.

'There is a substantial need for new approaches to help drug addicts overcome
their habit,' said David Oxlade, Chief Executive of Xenova.  'TA-CD has made
promising progress in earlier clinical studies and this additional trial is
designed to show for the first time whether addicts' behaviour can be altered by
administration of the TA-CD vaccine,' he added.

                                    - ends -

UK:                                        US:
Xenova Group plc                           Trout Group/BMC Communications
Tel: +44 (0)1753 706600                    Tel: 001 212 477 9007
David A Oxlade, 
Chief Executive Officer                    Press: Brad Miles (Ext 17) 
Daniel Abrams,                             Lauren Tortorete (Ext 20)
Group Finance Director                     Investors: Jonathan Fassberg 
Jon Davies, Corporate                      (Ext 16) Lee Stern (Ext 22)

Financial Dynamics
Tel: +44 (0)207 831 3113
David Yates/Ben Atwell

                                Notes to Editors

Xenova Group plc's product pipeline focuses principally on the therapeutic areas
of cancer and immune system disorders.  Xenova has a broad pipeline of
programmes in clinical development.  The Group has a well-established track
record in the identification, development and partnering of innovative products
and technologies and has partnerships with significant pharmaceutical and
biopharmaceutical companies including Lilly, Pfizer, Celltech, Genentech, QLT
and Millennium Pharmaceuticals.

TA-CD is designed for use alongside a behavioural therapy program in patients
who are trying actively to overcome their cocaine addiction. TA-CD represents a
completely new approach to the treatment of cocaine addiction by way of immune
intervention.  The vaccine aims to build an antibody response against the drug
which will neutralize its effect on the brain.  The results of an earlier
four-dose Phase IIa dose escalation study, which were reported in July 2001,
found that TA-CD was well tolerated both systemically and locally, and an
attenuation of the usual euphoric effects of cocaine was reported amongst five
of six patients who relapsed during the study, providing anecdotal evidence of
the benefit TA-CD may provide.  In April 2002 patient dosing began in an open
label Phase IIa dose escalation trial for TA-CD, which was designed to evaluate
the safety and immunogenicity of TA-CD using a 4 or 5 dose vaccination schedule.
This study is being funded in part by the National Institute on Drug Abuse
(NIDA). NIDA has also supported earlier clinical work as part of this program.

Regular cocaine users number more than two million in the U.S. alone.  Of these,
approximately 900,000 seek treatment each year.  Most cocaine addicts are
treated by a specialist physician or psychiatrist in drug rehabilitation
centres. However, due to a high relapse rate reported with current treatment,
there is a clear need for an effective treatment to be used alongside a
behavioural therapy program, where currently nothing is available.

For further information about Xenova and its products please visit the Xenova
website at

For Xenova: Disclaimer to take advantage of the 'Safe Harbor' provisions of the
US Private Securities Litigation Reform Act of 1995. This press release contains
'forward-looking statements,' including statements about the discovery,
development and commercialization of products. Various risks may cause Xenova's
actual results to differ materially from those expressed or implied by the
forward looking statements, including: adverse results in our drug discovery and
clinical development programs; failure to obtain patent protection for our
discoveries; commercial limitations imposed by patents owned or controlled by
third parties; our dependence upon strategic alliance partners to develop and
commercialize products and services; difficulties or delays in obtaining
regulatory approvals to market products and services resulting from our
development efforts; the requirement for substantial funding to conduct research
and development and to expand commercialization activities; and product
initiatives by competitors.  For a further list and description of the risks and
uncertainties we face, see the reports we have filed with the Securities and
Exchange Commission.  We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.

                      This information is provided by RNS
            The company news service from the London Stock Exchange                                                                                                               

a d v e r t i s e m e n t